iDISCO Applications

What is iDISCO?

iDISCO is a method developed by Renier and co., whereby immunolabelling is combined with a method which effectively makes biological tissues transparent (3DISCO). This means that you are not only able to label tissue, but also you are able to see labels within a 3D block of tissue. Complex structures, such as axonal tracts, cannot easily be determined by 2D imaging, therefore 3D imaging is preferable to view such structures.

iDISCO: Adult mouse kidney

Visualizing FOXP2 in Mouse Brain

FOXP2 is a transcription factor involved in vocalization, and is present throughout the brain. Transcription factors are proteins which help the transcription of DNA into mRNA, which in turn gets translated into proteins. Renier and co. used iDISCO to see if FOXP2 could be detected in mouse brains, and they found that FOXP2 could be seen deep within the brain. This confirmed the findings of other researchers, who used different methods.

Visualizing Axonal Projections

Axons are projections from neurons (nerve cells) which carry nerve impulses away from the neuron to neighboring neurons or muscles. Due to the range that nerve cells need to cover, these axons can be extremely long. Renier and co. used antibodies that targeted specific neurons in mouse embryos and brains, and showed that iDISCO made it possible to visualize these neurons in mouse embryo heads without dissection. It was also possible to visualize neurons and their projections within certain parts of the adult mouse brain. This technique was also used to successfully visualize other types of neurons.

Does iDISCO Work with Transgenic Markers?

Antibodies cannot be used to visualize all types of structures, therefore Renier and co. set about to see if markers expressed by transgenic mice can be visualized using iDISCO. Several techniques, including the use of fluorescent markers and epitope tags like LacZ showed that iDISCO can be used. This included the visualization of specific types of neurons, and using an antibody to detect the LacZ product to visualize cells producing this marker.

Studying Alzheimer’s Disease Using iDISCO

Alzheimer’s disease is a neurodegenerative disorder characterized by two hallmark changes within the brain: the accumulation of beta amyloid (β-amyloid) proteins leading to it aggregating within the brain (β-amyloid plaques), and the presence of intracellular neurofibrillary tangles (NFTs). It is still unclear how these hallmarks come to form, therefore the study by Liebmann set about to see if iDISCO can be utilized for this purpose.

Liebmann and co. first set about to see if β-amyloid plaques in mouse brains could be visualized by iDISCO. Initially, they used antibodies but then used Congo red, a small molecule known to bind to β-amyloid plaques. They found that antibodies and Congo red can be successfully used to visualize β-amyloid plaques in mouse brains. Using Congo red has the advantage that it only needs 2 hours before the dye is visible by iDISCO, which is much quicker than using antibodies.

Liebmann and co. verified that iDISCO gave a similar number of β-amyloid plaques when compared with a standardized technique for visualizing β-amyloid plaques known as immunohistochemistry, therefore iDISCO is as good as immunohistochemistry for detecting β-amyloid plaques.

The advantage of iDISCO is that large volumes of intact tissue can be visualized while maintaining good resolution of structures. The structures formed by β-amyloid plaques can be clearly seen using iDISCO. Therefore, iDISCO can be used to determine different structures formed by β-amyloid plaques.

Marking Immediate Early Genes to Study Brain Activity

Immediate Early Genes are genes which are switched on rapidly, and do not require the involvement of other proteins. Some Immediate Early Genes, such as c-Fos, ARC, EGR1, FOSB and NPAS4, have been used in the past as a way to determine brain activity. Therefore, Ranier and co. specifically labelled Immediate Early Genes and used the iDISCO approach to visualize the activity of Immediate Early Genes.

In this study, Ranier and co. modified the iDISCO so that the sample did not shrink, and this means that the image produced by the modified iDISCO, or iDISCO+, can be compared to a reference.

Further Reading

Last Updated: Jul 21, 2023

Dr. Maho Yokoyama

Written by

Dr. Maho Yokoyama

Dr. Maho Yokoyama is a researcher and science writer. She was awarded her Ph.D. from the University of Bath, UK, following a thesis in the field of Microbiology, where she applied functional genomics to Staphylococcus aureus . During her doctoral studies, Maho collaborated with other academics on several papers and even published some of her own work in peer-reviewed scientific journals. She also presented her work at academic conferences around the world.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Yokoyama, Maho. (2023, July 21). iDISCO Applications. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/life-sciences/iDISCO-Applications.aspx.

  • MLA

    Yokoyama, Maho. "iDISCO Applications". News-Medical. 21 November 2024. <https://www.news-medical.net/life-sciences/iDISCO-Applications.aspx>.

  • Chicago

    Yokoyama, Maho. "iDISCO Applications". News-Medical. https://www.news-medical.net/life-sciences/iDISCO-Applications.aspx. (accessed November 21, 2024).

  • Harvard

    Yokoyama, Maho. 2023. iDISCO Applications. News-Medical, viewed 21 November 2024, https://www.news-medical.net/life-sciences/iDISCO-Applications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.